| TITLE |
DATE |
| Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim® |
6-Dec-2011 |
| PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 |
28-Nov-2011 |
| PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference |
16-Nov-2011 |
| PharmAthene Reports Third Quarter 2011 Financial and Operating Results |
9-Nov-2011 |
| PharmAthene Appoints Linda L. Chang Senior Vice President, Chief Financial Officer |
9-Nov-2011 |
| PharmAthene to Host Third Quarter 2011 Conference Call and Webcast on Wednesday, November 9, 2011 |
4-Nov-2011 |
| PharmAthene Progresses Second Generation rPA Anthrax Vaccine |
31-Oct-2011 |
| PharmAthene Submits Legal Brief in Response to SIGA Technologies' Motion for Reargument |
13-Oct-2011 |
| WMD Research Center Gives the Country's Biopreparedness Effort a "D" for Medical Countermeasures Development and Availability |
12-Oct-2011 |
| PharmAthene Appoints Brian A. Markison to the Company's Board of Directors |
26-Sep-2011 |
| PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court |
22-Sep-2011 |
| PharmAthene Achieves Significant Progress in SparVax(TM) Anthrax Vaccine Program |
9-Sep-2011 |
| NYSE Amex Required Update |
29-Aug-2011 |
| Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program |
16-Aug-2011 |
| PharmAthene Reports Second Quarter 2011 Financial and Operating Results |
10-Aug-2011 |
| Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors |
15-Jul-2011 |
| PharmAthene's rPA Anthrax Vaccine Program Demonstrates 36 Month Product Stability |
12-Jul-2011 |
| PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index |
28-Jun-2011 |
| PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer |
27-Jun-2011 |
| PharmAthene Completes $6.5 Million Registered Direct Offering |
15-Jun-2011 |
| PharmAthene Announces $6.5 Million Registered Direct Offering |
10-Jun-2011 |
| PharmAthene Reports First Quarter 2011 Financial and Operating Results |
11-May-2011 |
| PharmAthene Completes Closing Arguments and Provides Update on Litigation With SIGA Technologies |
2-May-2011 |
| PharmAthene Completes Dosing in Valortim(R) Phase I Clinical Trial |
13-Apr-2011 |
| PharmAthene Reports Year-End 2010 Financial and Operating Results |
28-Mar-2011 |
| PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011 |
16-Mar-2011 |
| PharmAthene to Present at the ROTH Capital Partners 23rd Annual Growth Stock Conference on March 14, 2011 |
11-Mar-2011 |
| PharmAthene Presents New Anthrax Anti-Toxin Data at the ASM Biodefense and Emerging Diseases Research Meeting |
8-Feb-2011 |
| PharmAthene Provides Update on Litigation With SIGA Technologies |
24-Jan-2011 |
| PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day |
13-Jan-2011 |
| PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth |
10-Jan-2011 |
| PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim® |
9-Dec-2010 |
| Delaware Court Denies SIGA's Motion for Partial Summary Judgment in its Entirety |
24-Nov-2010 |
| PharmAthene Announces Full Exercise of Over-Allotment Option |
24-Nov-2010 |
| PharmAthene Reports Third Quarter 2010 Financial and Operational Results |
11-Nov-2010 |
| PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010 |
4-Nov-2010 |
| PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 |
4-Nov-2010 |
| PharmAthene Announces Closing of $15 Million Public Offering |
3-Nov-2010 |
| PharmAthene Announces Pricing of $15 Million Public Offering |
29-Oct-2010 |
| PharmAthene Announces Proposed Common Stock Offering |
28-Oct-2010 |
| PharmAthene Appoints Eric I. Richman President and Chief Executive Officer |
21-Oct-2010 |
| PharmAthene Listing Compliance Plan Accepted by the NYSE Amex |
14-Oct-2010 |
| PharmAthene Reports Second Quarter 2010 Financial and Operational Results |
12-Aug-2010 |
| PharmAthene to Host Second Quarter 2010 Conference Call and Webcast on Thursday, August 12, 2010 |
5-Aug-2010 |
| PharmAthene Provides Update on NYSE Amex Listing Compliance Plan |
30-Jul-2010 |
| PharmAthene Completes Previously Announced Registered Direct Offering |
23-Jul-2010 |
| PharmAthene Announces $3.9 Million Registered Direct Offering |
20-Jul-2010 |
| PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity |
15-Jul-2010 |
| PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health |
8-Jul-2010 |
| U.S. Government Accountability Office Denies Competitor Protest of SparVax(TM) Contract Modification |
9-Jun-2010 |
| PharmAthene to Present at the Noble Financial Sixth Annual Equity Conference on Monday, June 7, 2010 |
1-Jun-2010 |
| PharmAthene Reports First Quarter 2010 Financial and Operational Results |
11-May-2010 |
| PharmAthene to Host First Quarter 2010 Conference Call and Webcast on Tuesday, May 11, 2010 |
5-May-2010 |
| PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference |
4-May-2010 |
| PharmAthene Appoints Eric I. Richman as Interim Chief Executive Officer |
3-May-2010 |
| PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors |
28-Apr-2010 |
| PharmAthene to Raise $2.5 Million From a Single Existing Investor in a Registered Direct Financing |
8-Apr-2010 |
| PharmAthene Appoints Industry Leader Thomas R. Fuerst Chief Scientific Officer |
5-Apr-2010 |
| PharmAthene Appoints Eric I. Richman as President and Chief Operating Officer and Announces Senior Management Promotions |
30-Mar-2010 |
| PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies |
23-Mar-2010 |
| PharmAthene to Provide Update on SparVax™ Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010 |
22-Mar-2010 |
| PharmAthene Contract Modification Subject to Suspension Pending Ruling on Competitor Protest |
19-Mar-2010 |
| PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 |
16-Mar-2010 |
| PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010 |
9-Mar-2010 |
| Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria |
24-Feb-2010 |
| PharmAthene Awarded up to Additional $78.4 Million Under Existing Contract for Advanced Development of SparVax(TM) Anthrax Vaccine |
23-Feb-2010 |
| PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine |
1-Feb-2010 |
| PharmAthene Updates Status of BARDA rPA Contract Discussions |
5-Jan-2010 |
| PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors |
21-Dec-2009 |
| PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision |
8-Dec-2009 |
| BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines |
7-Dec-2009 |
| PharmAthene Presents Phase I Clinical Trial Results and New Therapeutic Animal Model Data for Protexia® |
7-Dec-2009 |
| PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop |
4-Dec-2009 |
| PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop |
4-Dec-2009 |
| PharmAthene to Present Data for rPA Anthrax Vaccine, Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2009 |
1-Dec-2009 |
| PharmAthene Reports Third Quarter 2009 Financial and Operational Results |
12-Nov-2009 |
| PharmAthene To Host Third Quarter 2009 Conference Call and Webcast on Thursday, November 12, 2009 |
3-Nov-2009 |
| PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security |
5-Oct-2009 |
| PharmAthene to Present at The Maxim Group Growth Conference September 29, 2009 |
23-Sep-2009 |
| PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference |
3-Sep-2009 |
| PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009 |
1-Sep-2009 |
| PharmAthene Strengthens Senior Management Team; Appoints Charles A. Reinhart III Senior Vice President, Chief Financial Officer |
17-Aug-2009 |
| PharmAthene Reports Second Quarter 2009 Financial and Operational Results |
13-Aug-2009 |
| PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009 |
6-Aug-2009 |
| PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants |
31-Jul-2009 |
| PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants |
27-Jul-2009 |
| PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review |
9-Jul-2009 |
| PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) |
2-Jun-2009 |
| PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA |
22-May-2009 |
| PharmAthene Reports First Quarter 2009 Financial and Operational Results |
15-May-2009 |
| PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast |
8-May-2009 |
| PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009 |
7-May-2009 |
| PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program |
28-Apr-2009 |
| PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research |
28-Apr-2009 |
| Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology |
31-Mar-2009 |
| PharmAthene Reports Year End 2008 Financial Results |
30-Mar-2009 |
| PharmAthene Announces $5.5 Million Public Equity Offering |
24-Mar-2009 |
| PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009 |
19-Mar-2009 |
| PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting |
24-Feb-2009 |
| PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel |
19-Nov-2008 |
| Pharmathene Reports Third Quarter 2008 Financial and Operational Results |
13-Nov-2008 |
| PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008 |
6-Nov-2008 |
| PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference |
4-Nov-2008 |
| Medarex And PharmAthene Announce New Therapeutic Data For Anthrax Anti-Toxin, Valortim® |
28-Oct-2008 |
| PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) |
27-Oct-2008 |
| PharmAthene to Present at the 7th Annual BIO Investor Forum in San Francisco |
23-Oct-2008 |
| PharmAthene Announces $1.6 Million Congressional Appropriation for Continued Development of Protexia® |
15-Oct-2008 |
| PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases |
13-Oct-2008 |
| PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases |
30-Sep-2008 |
| PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program |
26-Sep-2008 |
| PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop |
24-Sep-2008 |
| PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008 |
18-Sep-2008 |
| PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008 |
16-Sep-2008 |
| PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration |
15-Sep-2008 |
| PharmAthene Reports Second Quarter 2008 Financial and Operational Results |
12-Aug-2008 |
| Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene |
11-Aug-2008 |
| PharmAthene to Host Second Quarter 2008 Conference Call and Webcast on Tuesday, August 12, 2008 |
5-Aug-2008 |
| PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM) - A Recombinant Protective Antigen Vaccine |
31-Jul-2008 |
| PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel |
10-Jul-2008 |
| PharmAthene CEO Participates on Panel at the 6th Annual Biodefense Vaccines & Therapeutics Conference in Washington DC |
11-Jun-2008 |
| PharmAthene Reports First Quarter 2008 Financial Results |
13-May-2008 |
| PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, Mary 13, 2008 |
13-May-2008 |
| PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease |
9-Apr-2008 |
| PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit |
2-Apr-2008 |
| PharmAthene Reports Year-End 2007 Financial Results |
31-Mar-2008 |
| Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia® Program |
26-Mar-2008 |
| PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business from Avecia |
20-Mar-2008 |
| PharmAthene to Host Year-End 2007 Earnings Conference Call and Webcast on Thursday, March 20, 2008 |
13-Mar-2008 |
| PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference |
10-Mar-2008 |
| PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, PH.D. Senior Vice President of Operations |
8-Feb-2008 |
| PharmAthene to Present at the BIO CEO & Investor Conference 2008 |
6-Feb-2008 |
| Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA |
16-Jan-2008 |
| PharmAthene and Medarex Announce FY 2008 U.S. Congressional Appropriation of up to $1.6 Million for Continued Development of Anthrax Therapeutic Valortim™ |
8-Jan-2008 |
| PharmAthene Reports Third Quarter 2007 Financial Results |
13-Nov-2007 |
| PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim™ |
6-Nov-2007 |
| PharmAthene to Host Conference Call / Webcast Announcing its Third Quarter Financial Results on November 13, 2007 at 4:30 P.M. Eastern Time |
6-Nov-2007 |
| PharmAthene Awarded up to $13.9 Million NIH Contract to Develop Anthrax Anti-Toxin, Valortim™ with Medarex |
26-Sep-2007 |
| PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services |
24-Sep-2007 |
| Delaware Court of Chancery Determines Validity of PharmAthene Merger |
28-Aug-2007 |
| Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court |
13-Aug-2007 |
| PharmAthene Common Shares and Warrants to Resume Trading on the American Stock Exchange |
7-Aug-2007 |
| PharmAthene to Hold Investor Call Regarding Merger with HAQ |
7-Aug-2007 |
| Healthcare Acquisition Corp. and PharmAthene, Inc. File Certificate of Merger to Complete Acquisition; Confirmation to be Sought from Delaware Court of Chancery Regarding Stockholder Vote |
6-Aug-2007 |
| Healthcare Acquisition Corp. and PharmAthene Receive Stockholder Approval for Their Merger |
3-Aug-2007 |
| Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim™ |
31-Jul-2007 |
| PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research |
3-Apr-2007 |
| Anthrax Monoclonal Antibody Valortim™ Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection |
29-Mar-2007 |
| PharmAthene and Healthcare Acquisition Corp. Announce Definitive Merger Agreement |
22-Jan-2007 |
| PharmAthene Enhances Executive Leadership Team and Appoints Christopher C. Camut Vice President and Chief Financial Officer |
8-Jan-2007 |
| PharmAthene Receives Tech Company of the Year Award from Anne Arundel Tech Council |
6-Nov-2006 |
| PharmAthene Awarded $1.7 Million NIH Grant for Protexia® |
18-Oct-2006 |
| Medarex and PharmAthene Announce Phase I Results of Anthrax Therapeutic Valortim™ |
16-Oct-2006 |
| PharmAthene and Medarex Announce $1 Million Congressional Appropriation for Continued Development of Anthrax Therapeutic Valortim™ |
11-Oct-2006 |
| PharmAthene Awarded $213 Million Department of Defense Contract for Advanced Development of Protexia® |
25-Sep-2006 |
| PharmAthene Presents Data on Recombinant Human Butyrylcholinesterase Program at Bioscience Review 2006 |
12-Jun-2006 |
| PharmAthene and Medarex Receive Orphan Drug Designation for Valortim™ to Treat Anthrax Infection |
6-Mar-2006 |
| PharmAthene and Medarex Receive $2.05 Million Congressional Appropriation for Continued Development of Valortim™ for Prevention and Treatment of Anthrax Infection |
10-Jan-2006 |
| PharmAthene and Medarex Receive FDA Fast Track Designation for Valortim™ for Treatment of Anthrax Infection |
9-Jan-2006 |
| Strategic Biodefense Platform Earns PharmAthene Anne Arundel Technology Council ‘Innovator of the Year' Award |
14-Dec-2005 |
| Fully Human Anti-Anthrax Antibody Enlists Immune System to Neutralize Anthrax Toxin in Preclinical Studies |
11-Oct-2005 |
| PharmAthene and Medarex Announce Phase I Clinical Trial of Valortim™ |
8-Aug-2005 |
| PharmAthene Adds Premier Chemical Scavenger Franchise to its Leading Biological and Chemical Defense Portfolio |
10-Mar-2005 |
| Medarex and PharmAthene Form Alliance to Develop and Commercialize Fully-Human Anti-Anthrax Monoclonal Antibody |
6-Dec-2004 |
| PharmAthene Closes $50 Million in Series B Financing |
12-Oct-2004 |
| Developer of Anthrax Anti-toxin Names New Management Team |
19-Feb-2004 |
 |
